Effectiveness of combined superficial femoral artery endovascular therapy with popliteal-to-distal bypass: A paradigm shift in surgical open bypass for chronic limb-threatening ischemia

Abstract

Objectives

The purpose of this study was to evaluate the results of combining superficial femoral artery endovascular therapy with distal bypass originating from the popliteal artery as a method of lower extremity revascularization in patients with chronic limb-threatening ischemia.

Methods

The records of patients undergoing combined superficial femoral artery endovascular therapy with popliteal-to-distal bypass for chronic limb-threatening ischemia from January 2014 to April 2020 at a single institution were retrospectively reviewed. The patients’ background, operative details, and long-term outcomes were analyzed.

Results

Fifty-two popliteal-to-distal bypasses with superficial femoral artery endovascular therapy were performed in 49 patients (33 men; mean age, 76 ± 9 years; diabetes mellitus, 80%; end-stage renal disease with hemodialysis, 47%). The Trans-Atlantic Inter-Society Consensus II classification of superficial femoral artery–popliteal lesion was “A” in 8 (15%) patients, “B” in 14 (27%) patients, “C” in 24 (46%) patients, and “D” in 6 (12%) patients. The intervention for superficial femoral artery lesions was plain old balloon angioplasty in 4 patients, self-expandable nitinol stent in 15 patients, drug-coated balloon in 18 patients, drug-eluting stent in 4 patients, stent graft in 10 patients, and interwoven nitinol stent in 1 patient. Distal bypass originated from the above-knee popliteal artery in 9 (17%) limbs and the below-knee popliteal artery in 43 (83%) limbs. The most common outflow artery was the posterior tibial artery (44%). The mean follow-up period was 17 ± 17 months. The primary and secondary patency of the graft was 44% and 72%, respectively, at 1 year and 39% and 72%, respectively, at 3 years. Primary patency and freedom from clinical-driven target lesion revascularization of superficial femoral artery endovascular therapy lesions were 85% and 90%, respectively, at 1 year and 63% and 75%, respectively, at 3 years. Limb salvage was 97% at 1 year and 92% at 3 years. Wound healing was 67% at 6 months and 83% at 12 months.

Conclusions

Combined superficial femoral artery endovascular therapy with popliteal-to-distal bypass may be a promising approach for patients with chronic limb-threatening ischemia because of durable patency, acceptable wound healing, and good limb salvage.

Keywords

Distal bypass chronic limb-threatening ischemia endovascular therapy wound healing limb salvage

Get full access to this article

View all access options for this article.

References

Schamp

KBC

Meerwald

Reijnen

MMPJ

, et al. The ongoing battle between infrapopliteal angioplasty and bypass surgery for critical limb ischemia. Ann Vasc Surg 2012; 26: 1145–1153.

Bradbury

Adam

Bell

, et al. Bypass versus Angioplasty in Severe Ischemia of the Legs (BASIL) trial: An intention-to-treat analysis of amputation-free and overall survival in patients randomized to a bypass surgery-first or a balloon angioplasty-first revascularization strategy. J Vasc Surg 2010; 51: 5S–17S.

Veith

Gupta

Samson

, et al. Superficial femoral and popliteal arteries as inflow sites for distal bypass. Surgery 1981; 90: 980–990.

Lammer

Zeller

Haausegger

, et al. Heparin-boneded covered stents versus bare-metal stents for complex femoropopliteal artery lesions. the randomized VISTAR trial (Viabahn endopoprosthesis with PROPATEN bioactive surface [VIA] versus bare nitinol stent in the treatment of long lesions in superficial femoral artery occlusive disease). J Am Coll Cardiol 2013; 62: 1320–1327.

Schneider

Laird

Brodmann

, et al. Treatment effect of drug-coated balloons is durable to 3 years in the femoropopliteal arteries: long-term results of the IN.PACT SFA randomized trial. Circ Cardiovasc Interv 2018; 11: e005891.

Müller-Hülsbeck

Keirse

Zeller

, et al. Long-term results from the MAJESTIC trial of the eluvia paclitaxel-eluting stent for femoropopliteal treatment: 3-year follow-up. Cardiovasc Intervent Radiol 2017; 40: 1832–1838.

Garcia

Rosenfield

Metzger

, et al. SUPERB final 3-year outcomes using interwoven nitinol biomimetic supera stent. Cathet Cardiovasc Intervent 2017; 89: 1259–1267.

Aboyans

Ricco

Bartelink

MEL

, et al. 2017 ESC guidelines on the diagnosis and treatment of peripheral arterial diseases, in collaboration with the European Society for Vascular Surgery (ESVS): document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries endorsed by: the European Stroke Organization (ESO) the task force for the diagnosis and treatment of peripheral arterial disease of the European Society of Cardiology (ESC) and of the European Society for Vascular Surgery (ESVS). Eur Heart J 2018; 39: 763–816.

Wengerter

Yang

Veith

, et al. A twelve-year experience with the popliteal-to-distal artery bypass: the significance and management of proximal disease. J Vasc Surg 1992; 15: 143–149.

10.

Schanzer

Owens

Conte

, et al. Superficial femoral artery percutaneous intervention is an effective strategy to optimize inflow for distal orgin bypass grafts. J Vasc Surg 2007; 45: 740–743.

11.

Latis

Jensen

Benvenisty

, et al. Outcomes of combined superficial femoral endovascular revascularization and popliteal to distal bypass for patients with tissue loss. Ann Vasc Surg 2008; 22: 366–371.

12.

Marcucci

Accrocca

Gabrielli

, et al. Combining superficial femoral artery endovascular treatment with distal vein bypass. J Cardiovasc Surg 2015; 56: 383–391.

13.

Tsuji

Kitano

Sugimoto

Outcomes of popliteal-to-distal bypass combined with femoropopliteal artery endovascular treatment for critical limb ischemia. Ann Vasc Dis 2017; 10: 223–228.

14.

Rutherford

Baker

Ernst

, et al. Recommended standards for reports dealing with lower extremity ischemia: revised version. J Vasc Surg 1997; 26: 517–538.

15.

Kanda

Investigation of the freely-available easy-to-use software EZR for medical statistics. Bone Marrow Transpl 2013; 48: 452–458.

16.

Norgren

Hiatt

Dormandy

, et al. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC П). J Vasc Surg 2007; 45: S5–S67.

17.

Conte

Bradbury

Kolh

, et al. Global vascular guideline on management of chronic limb-threatening ischemia. Eur J Vasc Endovasc Surg 2019; 58: S1–S109.

18.

Albers

Romiti

Brochado-Neto

, et al. Meta-analysis of popliteal-to-distal vein bypass grafts for critical ischemia. J Vasc Surg 2006; 43: 498–503.

19.

Saxon

Coffman

Gooding

, et al. Long-term patency and clinical outcome of the viabahn stent-graft for femoropopliteal artery obstruction. J Vasc Interv Radiol 2007; 18: 1341–1349.

20.

Conrad

Crawford

Hanckney

, et al. Endovascular management of patients with critical limb ischemia. J Vasc Surg 2011; 53: 1020–1025.

21.

Ihnat

Duong

Taylor

, et al. Contemporary outcomes after superficial femoral artery angioplasty and stenting: the influence of TASC classification and runoff score. J Vasc Surg 2008; 47: 967–974.

22.

Davies

Saad

Peden

, et al. Impact of runoff on superficial femoral artery endoluminal interventions for rest and tissue loss. J Vasc Surg 2008; 48: 619–626.

23.

Davies

Saad

Mohiuddin

, et al.

Percutaneous superficial femoral artery interventions for claudications does runoff matter?

Ann Vasc Surg 2008; 22: 790–798.

24.

Mii

Tanaka

Kyuragi

, et al. Aggressive wound care by a multidisciplinary team improve wound healing after infrainguinal bypass in patients with critical limb ischemia. Ann Vasc Surg 2017; 41: 196–204.

25.

Azuma

Uchida

Kokubo

, et al.

Factors influencing wound healing of critical ischemia foot after bypass surgery: is the angiosome important in selecting bypass target artery?

Euro J Vasc Endovasc Surg 2012; 43: 322–328.